Group 1 - The core viewpoint of the article is that Zhonghong Medical (300981) is committed to leveraging its business and industry advantages while focusing on the healthcare sector [1] Group 2 - The actual controller of the company is the Xiamen State-owned Assets Supervision and Administration Commission [1] - The company is actively engaging with investors through interactive platforms to address inquiries [1]

Group 1 - The core viewpoint of the article highlights the role of Zhonghong Medical as a state-owned enterprise in Fujian, emphasizing its commitment to leveraging its business and industry advantages in the healthcare sector [1] - Zhonghong Medical is under the actual control of the Xiamen State-owned Assets Supervision and Administration Commission, which indicates strong governmental support [1] - The company expresses gratitude for investor interest and reiterates its focus on the medical and health industry [1]

Core Viewpoint - Zhonghong Medical (300981) is actively working to leverage its subsidiary's advantages in the context of the upcoming full closure of Hainan Free Trade Port, focusing on optimizing policy implementation, expanding market channels, and enhancing collaborative research and development [1] Group 1 - The company is responding to investor inquiries regarding the potential benefits of Hainan Free Trade Port's full closure for its subsidiary, Zhonghong Medical Supplies (Hainan) Co., Ltd [1] - The company aims to maximize the advantages of its subsidiary's location and industry through strategic initiatives [1] - The company expresses gratitude for investor interest and emphasizes its commitment to innovative development [1]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Core Points - Zhonghong Medical (300981.SZ) closed at 14.21 yuan, with a decline of 2.07%, and a total market capitalization of 6.094 billion yuan, currently in a state of breaking issue [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext board on April 27, 2021, with an initial public offering of 41.67 million shares at a price of 48.59 yuan per share [1] - The highest price recorded on the first day of trading was 159.80 yuan, marking the peak since its listing, followed by a downward trend in stock price [1] - The total funds raised from the IPO amounted to 2.025 billion yuan, with a net amount of 1.896 billion yuan, exceeding the originally planned fundraising by 1.317 billion yuan [1] - The initial fundraising plan was to raise 580 million yuan for the production of nitrile gloves and to supplement working capital [1] Financial Distribution - The total issuance costs for the IPO were 128 million yuan, with underwriting and sponsorship fees amounting to 107 million yuan [2] - For the 2022 fiscal year, the profit distribution plan included a cash dividend of 7.00 yuan per 10 shares (tax included) and a capital reserve transfer of 3 shares for every 10 shares, resulting in a total cash dividend of 210,004,200 yuan [2] - The total share capital increased by 90,001,800 shares following the 2022 distribution [2] - For the 2021 fiscal year, the profit distribution plan included a cash dividend of 30.00 yuan per 10 shares (tax included) and a capital reserve transfer of 8 shares for every 10 shares, leading to a total cash dividend of 500,010,000 yuan [2] - The total share capital increased by 133,336,000 shares after the 2021 distribution [2] Future Projections - The 2024 profit distribution plan, announced for June 20, 2025, proposes a cash dividend of 2.5 yuan per 10 shares (tax included) and a capital reserve transfer of 1 share for every 10 shares, totaling a cash dividend of 97,142,899.50 yuan [3] - The total share capital is projected to increase to 428,864,960 shares after the 2024 distribution [3]

格隆汇11月27日丨中红医疗(300981.SZ)公布，子公司江西科伦医疗器械制造有限公司于近期取得国家 药品监督管理局颁发的《中华人民共和国医疗器械注册证》，上述注册证为原有产品的延续注册，有效 期限由原2025年10月26日到期延续至2030年11月24日到期。上述医疗器械注册证有效期的延长，延续了 公司及子公司在一次性使用无菌低阻力注射器（带针）领域的产品品类，能够保证原有产品的持续销 售，并将进一步增强公司及子公司的综合竞争力，不断满足多元化的市场需求，有利于进一步提高市场 拓展能力。 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-103 中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局颁发的《中华人民共和国医疗 器械注册证》，上述注册证为原有产品的延续注册，有效期限由原 2025 年 10 月 26 日到期延续至 2030 年 11 月 24 日到期。上述注册证具体情况如下： 1. 《中华人民共和国医疗器械注册证》。 一、基本信息 | 注册人名称 | 产品名称 | 注册证编号 | 注册分类 | 注册证有效期 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 江西科伦医 疗器械制造 | 一次性使用无 菌低阻力注射 | 国械注准 | Ⅲ类 | 2025年 11 月 25日至 | 本 产 品 供 抽 吸 液 体 或 在 注 入 液 体 | | | | 20153142230 | | 2030 年 11 月 24 日 | | | 有限公司 | 器 带针 | | | | 后立即注射用。 | 二、对公司的影响及风险提示 上述医疗器械注册证有效期 ...

投资者提问：董秘你好，天猫、京东、拼多多等电商平台上的"倍力乐"旗舰店是公司的品牌么？ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，中红医疗(300981)11月27日在投资者关系平台上答复投资者关心的问题。 中红医疗回复：尊敬的投资者，您好！"倍力乐"为公司旗下避孕套品牌。"中红"及"倍力乐"为中红医疗 旗下避孕套产品的两大核心品牌，其产品涵盖聚氨酯、聚异戊二烯、天然乳胶等多种材质。感谢您对公 司的关注。 ...

Core Viewpoint - Zhonghong Medical (300981.SZ) is currently experiencing a decline in stock price, closing at 14.59 yuan with a drop of 3.63%, indicating a state of breaking down since its IPO in April 2021 [1] Group 1: IPO and Initial Performance - Zhonghong Medical was listed on the Shenzhen Stock Exchange's ChiNext on April 27, 2021, with an initial public offering of 41.67 million shares at a price of 48.59 yuan per share [1][2] - On its first trading day, the stock reached a peak price of 159.80 yuan, marking the highest price since its listing, but has since experienced a downward trend [2] - The total funds raised from the IPO amounted to 2.025 billion yuan, with a net amount of 1.896 billion yuan, exceeding the originally planned fundraising by 1.317 billion yuan [2] Group 2: Use of Proceeds and Financial Performance - The initial plan for the raised funds was 580 million yuan, allocated for the nitrile glove project at Jiangxi Zhonghong Pulin Medical Products Co., Ltd. and for supplementing working capital [2] - The total issuance costs for the IPO were 128 million yuan, with underwriting and sponsorship fees accounting for 107 million yuan [3] Group 3: Dividend Distribution - In 2022, the company announced a profit distribution plan, distributing 7.00 yuan in cash per 10 shares (including tax) and increasing the total share capital by 9 million shares through capital reserve [3] - For the 2021 fiscal year, the company distributed 30.00 yuan in cash per 10 shares (including tax) and increased the total share capital by 13.33 million shares [3] - A future dividend plan for June 10, 2025, includes a distribution of 2.5 yuan in cash per 10 shares (pre-tax) and a share increase of 1 share for every 10 shares held [4]

Core Viewpoint - 中红医疗 is experiencing a decline in stock price and trading volume, with a market capitalization of 6.257 billion yuan and a trading volume of 188 million yuan on November 26, showing a decrease of 3.63% [1] Group 1: Business Overview - 中红医疗 specializes in the research, production, and sales of high-quality medical and industrial disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9] - The company primarily engages in ODM direct sales, producing medical devices and consumables for overseas brand owners, who handle packaging design and marketing [3] - As of September 30, 中红医疗 reported an overseas revenue share of 81.56%, benefiting from the depreciation of the yuan [4] Group 2: Recent Developments - 中红医疗 is collaborating with 桂林理工大学 to develop a multi-layer nuclear radiation protective glove, addressing the technical needs outlined in its 2024 ESG report [2] - The company showcased its veterinary infusion pumps at the 12th Beijing Pet Expo, which received positive feedback for their safety and multifunctionality [2] Group 3: Financial Performance - For the period from January to September 2025, 中红医疗 achieved a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% [10] - Since its A-share listing, 中红医疗 has distributed a total of 1.251 billion yuan in dividends, with 501 million yuan in the last three years [11] Group 4: Shareholder Information - As of September 30, 2025, 中红医疗 had 22,400 shareholders, an increase of 11.24%, with an average of 17,531 circulating shares per person, a decrease of 10.11% [10] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and a newly entered medical device ETF [11]